CDKN2A is an inclusion criterion in 74 clinical trials for oropharyngeal squamous cell carcinoma, of which 64 are open and 10 are closed. Of the trials that contain CDKN2A status and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 6 are phase 1 (5 open), 4 are phase 1/phase 2 (3 open), 48 are phase 2 (44 open), 1 is phase 2/phase 3 (1 open), 7 are phase 3 (5 open), and 7 are no phase specified (5 open) [4].

CDKN2A is an inclusion criterion in 46 clinical trials for head and neck squamous cell carcinoma, of which 38 are open and 8 are closed. Of the trials that contain CDKN2A status and head and neck squamous cell carcinoma as inclusion criteria, 15 are phase 1 (12 open), 11 are phase 1/phase 2 (8 open), 19 are phase 2 (18 open), and 1 is no phase specified (0 open) [4].

CDKN2A is an inclusion criterion in 34 clinical trials for malignant solid tumor, of which 26 are open and 8 are closed. Of the trials that contain CDKN2A status and malignant solid tumor as inclusion criteria, 12 are phase 1 (8 open), 7 are phase 1/phase 2 (5 open), and 15 are phase 2 (13 open) [4].

CDKN2A is an inclusion criterion in 27 clinical trials for cervical carcinoma, of which 19 are open and 8 are closed. Of the trials that contain CDKN2A status and cervical carcinoma as inclusion criteria, 1 is early phase 1 (0 open), 7 are phase 1 (6 open), 12 are phase 1/phase 2 (7 open), 6 are phase 2 (5 open), and 1 is no phase specified (1 open) [4].

CDKN2A is an inclusion criterion in 16 clinical trials for oropharyngeal carcinoma, of which 13 are open and 3 are closed. Of the trials that contain CDKN2A status and oropharyngeal carcinoma as inclusion criteria, 3 are phase 1 (2 open), 5 are phase 1/phase 2 (4 open), 5 are phase 2 (4 open), 1 is phase 2/phase 3 (1 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open) [4].

CDKN2A is an inclusion criterion in 13 clinical trials for anal carcinoma, of which 8 are open and 5 are closed. Of the trials that contain CDKN2A status and anal carcinoma as inclusion criteria, 3 are phase 1 (2 open), 6 are phase 1/phase 2 (3 open), 2 are phase 2 (2 open), and 2 are no phase specified (1 open) [4].

CDKN2A is an inclusion criterion in 12 clinical trials for hypopharyngeal squamous cell carcinoma, of which 11 are open and 1 is closed. Of the trials that contain CDKN2A status and hypopharyngeal squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (5 open), 3 are phase 3 (2 open), and 1 is no phase specified (1 open) [4].

CDKN2A is an inclusion criterion in 12 clinical trials for penile carcinoma, of which 8 are open and 4 are closed. Of the trials that contain CDKN2A status and penile carcinoma as inclusion criteria, 3 are phase 1 (2 open), 6 are phase 1/phase 2 (3 open), 2 are phase 2 (2 open), and 1 is no phase specified (1 open) [4].

CDKN2A is an inclusion criterion in 12 clinical trials for vaginal carcinoma, of which 8 are open and 4 are closed. Of the trials that contain CDKN2A status and vaginal carcinoma as inclusion criteria, 3 are phase 1 (2 open), 6 are phase 1/phase 2 (3 open), 2 are phase 2 (2 open), and 1 is no phase specified (1 open) [4].

CDKN2A is an inclusion criterion in 12 clinical trials for vulvar carcinoma, of which 8 are open and 4 are closed. Of the trials that contain CDKN2A status and vulvar carcinoma as inclusion criteria, 3 are phase 1 (2 open), 6 are phase 1/phase 2 (3 open), 2 are phase 2 (2 open), and 1 is no phase specified (1 open) [4].

CDKN2A is an inclusion criterion in 11 clinical trials for head and neck squamous cell carcinoma of unknown primary, of which 11 are open and 0 are closed. Of the trials that contain CDKN2A status and head and neck squamous cell carcinoma of unknown primary as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 6 are phase 2 (6 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open) [4].

CDKN2A is an inclusion criterion in 10 clinical trials for laryngeal squamous cell carcinoma, of which 9 are open and 1 is closed. Of the trials that contain CDKN2A status and laryngeal squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (5 open), and 2 are phase 3 (1 open) [4].

CDKN2A is an inclusion criterion in 10 clinical trials for non-small cell lung carcinoma, of which 8 are open and 2 are closed. Of the trials that contain CDKN2A status and non-small cell lung carcinoma as inclusion criteria, 5 are phase 1 (4 open), 1 is phase 1/phase 2 (0 open), and 4 are phase 2 (4 open) [4].

CDKN2A is an inclusion criterion in 10 clinical trials for oral cavity squamous cell carcinoma, of which 8 are open and 2 are closed. Of the trials that contain CDKN2A status and oral cavity squamous cell carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (4 open), and 3 are phase 3 (2 open) [4].

CDKN2A is an inclusion criterion in 9 clinical trials for high grade cervical intraepithelial neoplasia, of which 6 are open and 3 are closed. Of the trials that contain CDKN2A status and high grade cervical intraepithelial neoplasia as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1 (1 open), 3 are phase 2 (3 open), and 2 are phase 3 (1 open) [4].

CDKN2A is an inclusion criterion in 9 clinical trials for melanoma, of which 8 are open and 1 is closed. Of the trials that contain CDKN2A status and melanoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [4].

CDKN2A is an inclusion criterion in 8 clinical trials for cervical squamous cell carcinoma, of which 8 are open and 0 are closed. Of the trials that contain CDKN2A status and cervical squamous cell carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (4 open), and 1 is no phase specified (1 open) [4].

CDKN2A is an inclusion criterion in 6 clinical trials for breast carcinoma, of which 3 are open and 3 are closed. Of the trials that contain CDKN2A status and breast carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 4 are phase 2 (2 open) [4].

CDKN2A is an inclusion criterion in 6 clinical trials for colorectal carcinoma, of which 3 are open and 3 are closed. Of the trials that contain CDKN2A status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 5 clinical trials for bladder carcinoma, of which 3 are open and 2 are closed. Of the trials that contain CDKN2A status and bladder carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 2 (2 open) [4].

CDKN2A is an inclusion criterion in 5 clinical trials for glioblastoma, of which 3 are open and 2 are closed. Of the trials that contain CDKN2A status and glioblastoma as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (1 open), and 2 are phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 5 clinical trials for nasopharyngeal squamous cell carcinoma, of which 5 are open and 0 are closed. Of the trials that contain CDKN2A status and nasopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open) [4].

CDKN2A is an inclusion criterion in 5 clinical trials for non-hodgkin lymphoma, of which 4 are open and 1 is closed. Of the trials that contain CDKN2A status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (3 open) [4].

CDKN2A is an inclusion criterion in 5 clinical trials for ovarian carcinoma, of which 2 are open and 3 are closed. Of the trials that contain CDKN2A status and ovarian carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 4 clinical trials for anal squamous cell carcinoma, of which 4 are open and 0 are closed. Of the trials that contain CDKN2A status and anal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].

CDKN2A is an inclusion criterion in 4 clinical trials for head and neck carcinoma, of which 3 are open and 1 is closed. Of the trials that contain CDKN2A status and head and neck carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (2 open) [4].

CDKN2A is an inclusion criterion in 4 clinical trials for lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain CDKN2A status and lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].

CDKN2A is an inclusion criterion in 4 clinical trials for lymphoma, of which 2 are open and 2 are closed. Of the trials that contain CDKN2A status and lymphoma as inclusion criteria, 4 are phase 1 (2 open) [4].

CDKN2A is an inclusion criterion in 4 clinical trials for nasopharyngeal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain CDKN2A status and nasopharyngeal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

CDKN2A is an inclusion criterion in 4 clinical trials for pancreatic carcinoma, of which 3 are open and 1 is closed. Of the trials that contain CDKN2A status and pancreatic carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (2 open) [4].

CDKN2A is an inclusion criterion in 4 clinical trials for tonsillar squamous cell carcinoma, of which 4 are open and 0 are closed. Of the trials that contain CDKN2A status and tonsillar squamous cell carcinoma as inclusion criteria, 4 are phase 2 (4 open) [4].

CDKN2A is an inclusion criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain CDKN2A status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 3 clinical trials for cervical intraepithelial neoplasia, of which 1 is open and 2 are closed. Of the trials that contain CDKN2A status and cervical intraepithelial neoplasia as inclusion criteria, 3 are phase 1 (1 open) [4].

CDKN2A is an inclusion criterion in 3 clinical trials for esophageal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain CDKN2A status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 3 clinical trials for malignant glioma, of which 3 are open and 0 are closed. Of the trials that contain CDKN2A status and malignant glioma as inclusion criteria, 3 are early phase 1 (3 open) [4].

CDKN2A is an inclusion criterion in 3 clinical trials for prostate carcinoma, of which 2 are open and 1 is closed. Of the trials that contain CDKN2A status and prostate carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [4].

CDKN2A is an inclusion criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain CDKN2A status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 2 are phase 2 (2 open) [4].

CDKN2A is an inclusion criterion in 3 clinical trials for squamous cell carcinoma of unknown primary, of which 3 are open and 0 are closed. Of the trials that contain CDKN2A status and squamous cell carcinoma of unknown primary as inclusion criteria, 3 are phase 2 (3 open) [4].

CDKN2A is an inclusion criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain CDKN2A status and urothelial carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (0 open) [4].

CDKN2A is an inclusion criterion in 2 clinical trials for anal intraepithelial neoplasia, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A status and anal intraepithelial neoplasia as inclusion criteria, 2 are phase 1 (1 open) [4].

CDKN2A is an inclusion criterion in 2 clinical trials for anaplastic astrocytoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A status and anaplastic astrocytoma as inclusion criteria, 2 are phase 1 (1 open) [4].

CDKN2A is an inclusion criterion in 2 clinical trials for cancer, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A status and cancer as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [4].

CDKN2A is an inclusion criterion in 2 clinical trials for cervical adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A status and cervical adenocarcinoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 2 clinical trials for cervical adenosquamous carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A status and cervical adenosquamous carcinoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 2 clinical trials for esophageal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 2 clinical trials for gastric adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 2 clinical trials for gastric carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

CDKN2A is an inclusion criterion in 2 clinical trials for malignant uterine neoplasm, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A status and malignant uterine neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 2 clinical trials for oral cavity carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A status and oral cavity carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 2 clinical trials for oropharyngeal undifferentiated carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A status and oropharyngeal undifferentiated carcinoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 2 clinical trials for rectal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A status and rectal squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 2 clinical trials for sarcoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A status and sarcoma as inclusion criteria, 2 are phase 1 (1 open) [4].

CDKN2A is an inclusion criterion in 2 clinical trials for vulvar squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A status and vulvar squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 2 clinical trials for vulvar/vaginal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A status and vulvar/vaginal squamous cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for acral lentiginous melanoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and acral lentiginous melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for adenoid cystic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and adenoid cystic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for anal canal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and anal canal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for appendix carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and appendix carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for breast adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and breast adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for cervical neuroendocrine carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and cervical neuroendocrine carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for chordoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and chordoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for dedifferentiated chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and dedifferentiated chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for fallopian tube carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A status and fallopian tube carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for laryngeal small cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and laryngeal small cell carcinoma as inclusion criteria, 1 is phase 3 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for lung papilloma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and lung papilloma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for malignant pleural mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and malignant pleural mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and meningioma as inclusion criteria, 1 is early phase 1 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for Merkel cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and Merkel cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for nasal cavity squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and nasal cavity squamous cell carcinoma as inclusion criteria, 1 is no phase specified (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for paranasal sinus squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and paranasal sinus squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for primary peritoneal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A status and primary peritoneal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for small intestinal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and small intestinal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for squamous cell carcinoma of the penis, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and squamous cell carcinoma of the penis as inclusion criteria, 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for supraglottic squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and supraglottic squamous cell carcinoma as inclusion criteria, 1 is no phase specified (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for tongue squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and tongue squamous cell carcinoma as inclusion criteria, 1 is no phase specified (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for transitional cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and transitional cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for vaginal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and vaginal squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for vulvar high grade squamous intraepithelial lesion, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A status and vulvar high grade squamous intraepithelial lesion as inclusion criteria, 1 is phase 1 (0 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for vulvar neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and vulvar neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for vulvar squamous intraepithelial lesion, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A status and vulvar squamous intraepithelial lesion as inclusion criteria, 1 is phase 2 (0 open) [4].

CDKN2A is an inclusion criterion in 1 clinical trial for well-differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and well-differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].